Antidepressant and antipsychotic drug prescribing in people with type 2 diabetes
dc.contributor.advisor
Jackson, Caroline
dc.contributor.advisor
Wild, Sarah
dc.contributor.advisor
Wu, Honghan
dc.contributor.advisor
Smith, Daniel
dc.contributor.author
Simpson-Greene, Charlotte R. L.
dc.contributor.sponsor
Medical Research Council (MRC)
en
dc.date.accessioned
2025-09-17T13:16:54Z
dc.date.available
2025-09-17T13:16:54Z
dc.date.issued
2025-09-17
dc.description.abstract
BACKGROUND:
Prescribing of antidepressant and antipsychotic drugs is increasing worldwide for a range of indications including mental illness. Prescribing of these drugs among people with type 2 diabetes (T2D) is higher relative to the general population, due to the higher prevalence of mental illness in people with diabetes as well as the use of some types of antidepressants in treating diabetic neuropathy. In addition, there is concern that the prescribing of antidepressant and antipsychotic drugs may lead to poorer outcomes in people with diabetes. However, the literature on this topic is limited.
METHODS:
This project was completed in three stages: (1) repeated annual cross-sectional
analyses describing prevalence of antidepressant and antipsychotic prescribing, overall and by sociodemographic factors and drug subtype, in people with T2D in Scotland from 2004 to 2021; (2) a systematic review of observational studies examining the association between
antidepressant or antipsychotic drugs and mortality, vascular morbidity, and cardiometabolic risk factors in people with T2D, and; (3) a retrospective cohort study using Cox proportional hazards models to estimate hazard ratios (HRs) for each of all-cause mortality, cardiovascular disease (CVD)-specific mortality, and major cardiovascular events (MCEs, comprising stroke and myocardial infarction) in people diagnosed with T2D in Scotland between 2006 and 2021, prescribed each of antidepressant and antipsychotic drugs in the five years prior to diagnosis of diabetes relative to people without the prescribing of interest. Fully adjusted models included covariates for age, sex, ethnicity, deprivation, smoking status, comorbidities, history of CVD, history of alcohol use disorders, hospital admission diagnosis of mental illness, and other psychotropic drug prescribing. Stages (1) and (3) were conducted using a population-based diabetes registry with 99% coverage of people with a diagnosis of diabetes in Scotland.
RESULTS:
Between 2004 and 2021, the number of people with a diagnosis of T2D in Scotland nearly doubled, from 161,915 to 309,288. Age-sex standardised annual prescribing prevalence of antidepressants increased from 20.0 per 100 person-years (95% CI 19.8-20.2) in 2004 to 33.3 per 100 person-years (95% CI 33.1-33.6) in 2021, while prescribing prevalence of antipsychotics increased from 2.8 per 100 person-years (95% CI 2.7-2.8) in 2004 to 4.7 per 100 person-years (95% CI 4.6-4.8) in 2021. This trend was consistent across most drug subtypes except first-generation antipsychotics, prescribing of which remained largely stable. Prescribing patterns also differed by age, sex, and socioeconomic status. The systematic review included 18 studies, 14 reporting on antidepressants and four on antipsychotics. While some evidence suggested that antidepressant prescribing may be associated with increased risk of CVD morbidity, and that both antidepressant and antipsychotic prescribing may impair glycaemic control, findings were mixed, and with significant methodological limitations. The retrospective cohort study of 240,657 people with T2D showed that antidepressant prescribing prior to diabetes diagnosis was associated with statistically significant or marginally statistically significant higher risk of each of allcause mortality, CVD-specific mortality, and MCEs in crude or partially adjusted models. However, these associations were not significant in fully adjusted models. By contrast, antipsychotic prescribing was associated with significantly higher risks of all-cause mortality (HR 1.31, 95% CI 1.24-1.37) and CVD-specific mortality (HR 1.19, 95% CI 1.09-1.30), but a lower risk of MCEs (HR 0.89, 95% CI 0.83-0.97) in fully adjusted models. Sensitivity analyses comparing second-generation antipsychotic prescribing with no antipsychotic prescribing yielded results consistent with the primary analyses.
CONCLUSION:
Increased prevalence of antidepressant and antipsychotic prescribing among people with T2D in Scotland between 2004 and 2021 potentially reflects the growing burden of multimorbidity in this population. Though the association between antidepressant prescribing prior to diabetes diagnosis and higher risk of each of all-cause mortality, CVDspecific mortality, and MCEs was not significant in fully adjusted models, the broader evidence base is mixed, and questions remain about potential long-term risks. Findings that antipsychotic prescribing prior to diabetes diagnosis was associated with significantly higher risk of all-cause and CVD-specific mortality raise concerns about the safety of these medications in people with T2D. Given the substantial public health burden of T2D and its associated complications, and the increasingly widespread use of antidepressant and antipsychotic drugs for a range of indications, it remains a priority to further advance our understanding of the prescribing of antidepressant and antipsychotic drugs in people with diabetes.
en
dc.identifier.uri
https://hdl.handle.net/1842/43976
dc.identifier.uri
http://dx.doi.org/10.7488/era/6506
dc.language.iso
en
en
dc.publisher
The University of Edinburgh
en
dc.relation.hasversion
Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: a time-trend analysis from 2004-2021 on behalf of The Scottish Diabetes Research Network Epidemiology Group, Greene, C., Blackbourn, L., McGurnaghan, S., Mercer, S. W., Smith, D., Wild, S. H., Honghan, W. & Jackson, C. A., 9 Jul 2024, In: British Journal of Clinical Pharmacology. 9 p
en
dc.relation.hasversion
Antidepressant and antipsychotic drug prescribing and diabetes outcomes: a systematic review of observational studies Greene, C., Ward-Penny, H., Ioannou, M. F., Wild, S. H., Wu, H., Smith, D. & Jackson, C. A., 1 May 2023, In: Diabetes Research and Clinical Practice. 199, 110649
en
dc.rights.embargodate
2026-09-17
en
dc.subject
antidepressant drugs
en
dc.subject
antipsychotic drugs
en
dc.subject
diabetes mellitus
en
dc.subject
type2
en
dc.subject
prescribing trends
en
dc.subject
primary health care
en
dc.subject
Scotland
en
dc.subject
Diabetes outcomes
en
dc.subject
Diabetes complications
en
dc.subject
Antidepressant medication
en
dc.subject
Antipsychotic medication
en
dc.subject
Systematic review
en
dc.title
Antidepressant and antipsychotic drug prescribing in people with type 2 diabetes
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Doctoral
en
dc.type.qualificationname
PhD Doctor of Philosophy
en
dcterms.accessRights
RESTRICTED ACCESS
en
Files
Original bundle
1 - 1 of 1
- Name:
- Simpson-GreeneSRL_2025.pdf
- Size:
- 5.11 MB
- Format:
- Adobe Portable Document Format
- Description:
- Cover sheet
This item appears in the following Collection(s)

